|
Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit
Antibody rapid tests depend on clear intended-use claims, sample handling, and local regulatory acceptance. The Bioperfectus kit is listed with CE-IVD status, defined sample types, and published sensitivity and specificity figures.
The Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test Kit is a Bioperfectus laboratory product for rapid diagnostic screening of IgM and IgG. The supplier states it is for trained personnel following instructions for use, laboratory procedures, and local regulatory requirements.
Technical data list human whole blood, serum, and plasma as sample types. Reported sensitivity is 80.8% for IgM, 90.8% for IgG, and 90.0% for IgG plus IgM; specificity is 98.4%, 97.1%, and 96.5%, respectively.
Storage is 4–30°C and transport is -20–45°C. Catalog SC30201W contains 20 tests per kit. These details affect shipping, stock rotation, and minimum order planning.
CE-IVD status signals compliance with one regulatory pathway, but local import, registration, and language requirements still need confirmation. Buyers should also verify whether the stated performance figures apply to their intended population and testing window.
The page does not describe automation, instrument compatibility, or quality-control procedures. Procurement should therefore confirm training, interpretation, and workflow fit before purchase.
Why it matters:
A rapid antibody test is only useful if its documented claims match the testing setting and regulatory market.
View Product →
|
ScientificChina — tracking China’s science, technology, and industrial systems through the lens of real-world products.
Follow ScientificChina for deeper insight into the infrastructure behind global innovation.
Visit ScientificChina.
ScientificChina is an independent commercial platform and is not affiliated with or endorsed by any Chinese government agency or public institution.
|
|
No products in the cart.